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Abstract
Background: The evaluation of more than one intervention in the same randomised controlled
trial can be achieved using a parallel group design. However this requires increased sample size and
can be inefficient, especially if there is also interest in considering combinations of the interventions.
An alternative may be a factorial trial, where for two interventions participants are allocated to
receive neither intervention, one or the other, or both. Factorial trials require special
considerations, however, particularly at the design and analysis stages.
Discussion: Using a 2 × 2 factorial trial as an example, we present a number of issues that should
be considered when planning a factorial trial. The main design issue is that of sample size. Factorial
trials are most often powered to detect the main effects of interventions, since adequate power to
detect plausible interactions requires greatly increased sample sizes. The main analytical issues
relate to the investigation of main effects and the interaction between the interventions in
appropriate regression models. Presentation of results should reflect the analytical strategy with an
emphasis on the principal research questions. We also give an example of how baseline and follow-
up data should be presented. Lastly, we discuss the implications of the design, analytical and
presentational issues covered.
Summary: Difficulties in interpreting the results of factorial trials if an influential interaction is
observed is the cost of the potential for efficient, simultaneous consideration of two or more
interventions. Factorial trials can in principle be designed to have adequate power to detect realistic
interactions, and in any case they are the only design that allows such effects to be investigated.
Background
Randomised controlled trials provide the best quality evi-
dence in medical research, [1] but they require a large
commitment of time and effort, certainly from the inves-
tigators and often from participants. As a result, trials can
be expensive. For these reasons, investigators may con-
sider evaluating more than one intervention in the same
study. For a controlled trial of two interventions, one
could consider a parallel three-arm trial, or even a four-
arm trial if two distinct control groups are required. An
example is a comparison of mailed guidelines with and
without an educational outreach visit from community
pharmacists to improve prescribing in general practice.[2]
If target differences for both interventions are identical,
these would require increases in sample size of 50% and
100% respectively compared with a two-arm trial.
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Correspondingly, the analyses would involve only two
thirds or half of the total sample size. Since the power to
detect treatment differences depends on the number of
participants in the groups being compared rather than the
total number in the trial, this can represent a rather ineffi-
cient use of resources.
An alternative may be a factorial trial, where participants
are allocated to receive neither intervention, one or the
other, or both. An example of such a trial is an evaluation
of two decision aids for newly diagnosed hypertensive
patients – that is, individual decision analysis and an
information video plus leaflet.[3] Other examples are a
factorial trial of two interventions to improve attendance
for breast screening,[4] and a factorial trial of two inter-
ventions to improve adherence to antidepressant
drugs.[5]
Although their use to date may have been limited,[6] fac-
torial trials have the potential to confer advantages over
the standard parallel-groups design. First, they enable effi-
cient simultaneous investigation of two interventions by
including all participants in both analyses. Second, it is
possible in a factorial trial to consider both the separate
effects of each intervention and the benefits of receiving
both interventions together. In order to realise these
advantages, however, factorial trials require some special
considerations, particularly at the design and analysis
stages. Although these issues have been discussed previ-
ously, [7] factorial trials continue to be often inappropri-
ately analysed and interpreted. The aim of this paper is to
explore these issues in the context of an individually ran-
domised 2 × 2 factorial trial, although in principle the
methods generalise to trials of more than two
interventions.
Discussion
Design considerations
The prime issue here is the sample size of the trial. The
most common procedure is to perform a separate calcula-
tion based on target effect sizes for each of the interven-
tions compared with their respective controls (Table 1).
The trial sample size is then simply the larger of these, and
the trial is said to be powered to detect the main effects of
each intervention. However, this sample size is based on
the crucial assumption that there is no interaction
between the interventions – in other words, that the effect
of intervention A does not differ depending on whether
participants also receive intervention B. This will by no
means always be a reasonable assumption, especially
where interventions involve behavioural and/or organisa-
tional change.
If a trial is to have adequate power to detect an interaction,
then the sample size will in general need to be increased.
For example, to detect with the same power an interaction
of the same magnitude as the main effects, a fourfold
increase in sample size is required (Table 2).[8] With no
increase in sample size, the interaction would need to be
at least twice as large as the main effects to be detected
with the same power;[8] this is very unlikely to be the case
in practice. Smaller, more plausible interactions would
require greatly increased sample sizes. If the interaction is
of primary interest then it is essential that the trial is pow-
ered to detect a reasonable target interaction effect.
If the primary comparisons are the main effects then the
approach in Table 1 is justifiable on grounds of efficiency.
At the same time, it should be appreciated that the result-
ant precision for the interaction may be inadequate to
exclude such an effect – that is, the confidence interval for
the interaction will be relatively wide. In other words, the
sample size will be insufficient to investigate the initial
assumption that the interaction is unimportant. Virtually
Table 1: Sample sizes required for 90% power and 1% two-sided alpha: main effects. Intervention A target difference = 0.35 standard 
deviations (SDs), total sample size = 486 (243 allocated to Intervention A, 243 allocated to the relevant control). Intervention B target 
difference = 0.3 SDs, total sample size = 664 (332 allocated to Intervention B, 332 allocated to the relevant control). A total sample size 
of n = 664 participants yields 90% power to detect differences of 0.3 SDs for Intervention B and 97% power to detect differences of 0.35 
SDs for Intervention A.
Intervention B
YES NO TOTAL
Intervention A YES 166 166 332
NO 166 166 332
TOTAL 332 332 664
To detect the same target differences with the same power and alpha in a three-arm parallel group trial would require 907 participants: 243 
allocated to Intervention A, and 332 allocated to each of Intervention B and control.BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/26
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identical arguments apply to interactions for binary out-
comes, although if logistic regression is used then the rel-
ative sizes of the interaction and main effects in Table 2
relate to the log odds scale.
Analytical considerations
The second consideration is the analytical strategy, which
should follow CONSORT guidelines.[9] In particular, the
primary analyses should address the principal research
questions. Table 3 presents the basic descriptive statistics
for the analysis of an example 2 × 2 factorial trial.[3] To
evaluate the decision analysis intervention, we compare
patients who received both interventions plus those who
received decision analysis only with patients who received
video and leaflet only plus those who received neither
intervention. In general, the correct analysis of such data
requires the use of a multivariable regression model, espe-
cially if the numbers of subjects in each of the four com-
binations shown in Table 3 are unequal (in technical
terms, if the design is 'unbalanced').
The approach in such models is essentially to obtain an
average of the two differences (28–44) and (27–33),
weighted according to the sample sizes. Regardless of the
technical details, conceptually the primary analysis is a
comparison of the margins of the 2 × 2 table. In the regres-
sion analyses, the effect of each intervention is adjusted
for the other intervention as well as any necessary covari-
ates, such as the outcome measure at baseline and stratifi-
cation variables. In the context of a randomised trial with
a continuous outcome, such adjustments are primarily to
improve precision, especially for individually randomised
trials. [10,11]. For binary outcomes, a multivariable
(logistic) regression analysis is required in order to obtain
correct estimates of the effects and their standard errors.
In focussing on the average effect of each intervention,
however, the above analysis assumes that the effect of
each intervention is uninfluenced by the presence or
absence of the other – that is, there is no interaction
between them. Since factorial trials are rarely powered to
detect interactions between the interventions, such effects
are usually investigated as a secondary analysis. These are
readily performed as extensions to the multivariable
regression models described above, by simply introducing
the appropriate interaction terms. However, the precision
of the estimates of interaction is very likely to be too poor
for large effects to be ruled out. In particular, a high p-
value will most likely reflect low power and so cannot be
taken as evidence for no interaction.
A special consideration for binary outcomes is the choice
of regression method. Logistic regression is commonly
used since, among other advantages, predicted propor-
tions from this model are constrained to be in the allow-
able range (that is, between zero and one). [12] Logistic
regression estimates odds ratios for the interventions and
assumes that these effects operate multiplicatively on this
scale. [13]
Table 2: Sample sizes required for 90% power and 1% two-sided alpha: interaction
Magnitude of effects (in units of standard deviations)
Main effect Interaction Total sample size to detect interaction
0.3 0.6 664
0.3 0.3 2656
0.3 0.15 10624
Table 3: Descriptive statistics for the primary outcome (crude mean decisional conflict scores[3]) for the analysis of a 2 × 2 factorial trial
Video and Leaflet
No Yes TOTAL
Decision analysis No 44 33 39
Y e s 2 82 72 8
TOTAL 37 30 34BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/26
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Presentation of results from a factorial trial
Regarding the results obtained at the main trial follow-up,
the primary analysis relating to the margins of the 2 × 2
table should give estimates (such as a difference, odds
ratio or risk ratio) and 95% confidence intervals compar-
ing those individuals allocated to receive an intervention
with those allocated to not receive it. The number of such
comparisons will be equal to the number of interventions
investigated in the trial. A common misunderstanding is
that the outcome measures should be analysed and pre-
sented separately for each of the four factorial cells, but to
do so would fail to realise the full efficiency and purpose
of the factorial design. Even in trials powered for main
effects, a test and confidence interval for the interaction
should be provided. An indication of the imprecision of
the results for the interaction is especially important given
the above concerns about the adequacy of the sample size
to investigate such effects. Table 4 demonstrates how the
results of the primary analyses in our example trial were
presented. [3]
In addition to the primary comparative statistics noted
above, it is also advisable to present descriptive statistics
for outcome measures at follow-up within each of the fac-
torial 'cells' in the trial (four in the case of a 2 × 2 design).
These can either be tabulated or included in the text of the
paper along with the regression coefficient and 95% con-
fidence interval for the interaction term. This allows inter-
pretation of the magnitude of any antagonism or
synergism between the interventions, and would of course
be essential if the interaction was the primary effect of
interest. In our example, there was a significant antagonis-
tic interaction, such that there was no added benefit from
a second intervention (Tables 3 and 4).
The most appropriate presentation of baseline data
depends on the original primary research question and
the results obtained. If an interaction is either posited or
observed, then descriptive baseline data for the four cells
is more helpful; otherwise, the margins are more relevant
to the issue of baseline comparability and correspond to
the primary analysis. With more than two interventions
the marginal approach increasingly becomes the only fea-
sible option.
Implications
Factorial designs provide an efficient method of evaluat-
ing more than one intervention in the absence of interac-
tions. This raises the question, however, of the degree of
certainty one might have in advance that there is no inter-
action between the interventions. Although Bayesian
methods might be helpful here in that they formalise such
prior information/beliefs, in practice there will be much
uncertainty, and so the issue is rather one of a judgement
as to how influential any likely interaction might be in the
context of the trial. In particular, if the direction of the
effect of intervention A is different for the levels of inter-
vention B (a 'qualitative' interaction) then a factorial trial
would be appropriate if this interaction was of key inter-
est, in which case the trial should be powered to detect the
interaction. If there is likely to be only a minor difference
in magnitude in the effect of intervention A across the lev-
els of intervention B (that is, a small 'quantitative' interac-
tion) then a factorial trial powered to detect the main
effects is more appropriate.[3] In any case, the practical
question of how to present the intervention effects in the
presence of a sizeable interaction remains. If the interac-
tion is qualitative then the main effects will almost
certainly be misleading and the cell means and interaction
effect together with separate estimates and confidence
intervals for the relevant subgroups will be the only
option. [14] For quantitative interactions such as in our
example, the main effects will over-estimate the effect for
some individuals and under-estimate it for others. Whilst
the interaction and the cell means must still be presented,
the main effects may nonetheless be a reasonable
representation of the intervention effects, both separately
and combined.
A factorial trial would be unsuitable for interventions that
could not be used in conjunction with one another, such
as two different minor surgical procedures for a dermato-
logical problem. For interventions such as those in Table
3, though, factorial trials are an especially useful option if
the principal interest is in comparing each intervention
Table 4: Presentation of the results of the primary analyses in a 2 × 2 factorial trial[3]
Decision Analysis n = 100 no Decision Analysis n = 112 Video/leaflet n = 104 no Video/leaflet n = 108
Total Decisional Conflict, mean (SD) 27.6 (12.1) 38.9 (18.3) 30.3 (13.4) 36.8 (18.8)
Adjusted difference1,2 (95% CI) -9.4 (-13.0 to -5.8)3 -4.2 (-7.8 to -0.6)3
p value < 0.001 0.021
1 Adjusted for age, sex, decisional conflict at baseline, factorial design and general practice (all comparisons are for the intervention compared with 
its respective control) 2 Negative differences represent a favourable outcome for the relevant intervention 3 The interaction between the 
interventions was investigated as a secondary analysis and was found to be significant (interaction coefficient = 12 (95% CI 5 to 19), p = 0.001)Publish with BioMed Central    and   every 
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with its respective control and also in considering if there
is any suggestion of an interaction between them. Indeed,
an appropriately powered factorial trial is the only design
that allows such effects to be investigated. Conversely, fac-
torial designs would be contra-indicated if primary inter-
est was in the direct comparison of the two interventions
applied individually – for example, decision analysis
alone versus video/leaflet alone.
The decision as to the suitability of the factorial design
must therefore take a number of issues into account – in
particular, the nature of the interventions, the setting of
the study including the participants, the comparisons of
interest and the outcome measure. For instance, interac-
tions may be considered to be more likely with behav-
ioural interventions, when as in our example the benefits
may be achieved with either intervention and there is rel-
atively little additional benefit from receiving a second
intervention.[3] In terms of the outcome measure, a con-
sideration for binary variables beyond the issues covered
in this paper is the choice of the statistical model
employed – that is, whether the effects of the interven-
tions are presumed to work additively in a linear model
for proportions, or multiplicatively as in a linear logistic
model. [12] Since the presence or absence of interactions
for a binary outcome depends on the statistical model
employed, choice of the latter is an important issue.
Summary
Difficulties in interpreting the results of factorial trials if
an influential interaction is observed should be recog-
nised as the cost of the potential for efficient, simultane-
ous consideration of two or more interventions. As
described in this paper, factorial trials can in principle be
designed to have adequate power to detect realistic inter-
actions, but this has major implications for the sample
size. On the other hand, unlike parallel groups trials a fac-
torial design does enable investigation of interactions in
the analysis, albeit with limited power. Researchers
should be aware of such issues when using factorial
designs.
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